Introduction
We previously demonstrated a decrease in the density of [ 3 H]phorbol 12,13-dibutyrate (PDBu) binding in the parahippocampal gyrus (PHG) from schizophrenic subjects. 1 This change in [ 3 H]PDBu binding was not present in other areas of the temporal lobe, the frontal cortex or the striatum. 2 Protein kinase C (PKC), an important component of second messenger cascades, was proposed to be the major binding site for phorbol esters. [3] [4] [5] However, it is now known that PKC exists as a number of isoforms varying in both distribution and cofactor requirements, 6 although only eight (␣, ␤I, ␤II, ␦, ⑀, ␥, and ) of the eleven PKC isoforms thus far identified have the structural requirements that allow the binding of phorbol esters. 7 Thus, our [ 3 H]PDBu binding data could suggest that there is a decrease in PKC in the PHG from subjects with schizophrenia. Therefore, identifying which PKC isoform is altered in the PHG from subjects with schizophrenia would be an important step in our understanding of the mechanism by which PKC could be involved in the neurobiology of the illness. To determine whether levels of the PKC isoforms were the cause of the reported change in [ 3 H]PDBu binding, we measured parameters of [ 3 H]PDBu binding and levels of the relevant isoforms in the PHG from subjects with schizophrenia. In addition, PKC activity was measured in membrane preparations of the PHG obtained from the same schizophrenic and control subjects. 
Materials and methods
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Tissue preparation
The tissue for this study came from subjects who were part of the cohort in which levels of [ 3 H]PDBu binding had previously been measured using autoradiography. 1 Tissue was obtained at autopsy, with ethical approval, from 15 subjects with a preliminary diagnosis of schizophrenia and from 15 subjects, matched for age and sex, with no history of mental illness (controls). The diagnosis of schizophrenia was confirmed, using the criteria for DSM-IV, 8 by a senior psychologist and a psychiatrist using the Diagnostic Instrument for Brain Studies. 9 From case histories, the duration of illness (DOI-the interval between the first hospital admission to time of death) and the last recorded antipsychotic doses, expressed as chlorpromazine equivalents, 10 were calculated (Table 1) . Where death was witnessed, the postmortem interval (PMI) was the time between death and autopsy. In cases where the death was not witnessed, the PMI was taken as being the interval halfway between the individual last being seen alive and being found dead. For all samples, the length of time the tissue was frozen at −70°C (freezer time, FT) was the time from autopsy to the date the tissue was removed for this study. In all cases the agonal status of the brain tissue was assessed by measuring the pH 11 of cerebellar tissue.
Crude particulate membranes were prepared as a total homogenate of the parahippocampal gyrus (5% w/v) in 20 mM Tris (pH 7.4), containing 0.1 mM EDTA, 0.2 mM EGTA, leupeptin, pepstatin A and chymotrypsin at 10 g ml , benzamidine at 1 mM and bacritracin at 1 mg ml −1 , as well as Complete  protease inhibitor cocktail at three times the recommended strength. The membranes were prepared on ice, using a handheld glass Teflon homogeniser. The protein concentrations were determined using the Bio-Rad modified Lowry protein assay adapted for the microplate. The membrane was then stored at −70°C in 200-l aliquots until required for the measurement of [ 3 H]PDBu binding and Western blots.
Tissue extracts for the PKC assay were prepared by homogenizing parahippocampal gyrus in 20% w/v extraction buffer (25 mM Tris pH 7.4, 0.5 mM EDTA, 0.5 mM EGTA, 0.05% Triton X-100, 10 mM mercaptoethanol, leupeptin and aprotinin at 1 g ml −1 and 0.5 mM phenylmethylsulphonyl fluoride) using a polytron. The homogenate was centrifuged at 14 000 × g for 5 min at 4°C. The supernatant was partially purified by chromatography through a Sephadex DEAE column. The samples were batch eluted with extraction buffer containing 200 mM NaCl. The concentration of protein in each fraction was measured using the Bio-Rad detergent compatible protein assay adapted for the microplate. The measurement of PKC activity was performed on the day that the extract was prepared. 3 H]PDBu binding was measured in the presence (non-specific) or absence (total) of non-radioactive phorbol-12, 13-dibutyrate at a concentration of 1 M. Bound and free radioligand were separated by filtration over Whatman GF/B using a Brandel Cell Harvester. Scatchard analyses and Hill plots were carried out using the EBDA program.
Western blots
Crude particulate membrane preparations were diluted in reducing buffer (0.125 M Tris-HCl pH 6.8, 5% glycerol, 4% sodium dodecyl sulphate, 1.42 M 2-mercaptoethanol, 0.0025% bromophenol blue) to give final protein levels of 0.33 mg ml . The proteins in each sample (10 g per lane) were separated using polyacrylamide gel electrophoresis (4% stacking gel and 10% running gel) at a constant voltage of 150 V. They were then transferred to nitrocellulose membranes overnight in Towbin transfer buffer 13 at a constant current of 40 mA.
After blocking in 5% non-fat milk powder, made with 0.1% Tween-20 in Tris-buffered saline, the nitrocellulose membranes were probed with antibodies for the PKC isoforms at empirically determined concentrations (mouse anti-PKC␣ 1/1000, anti-PKC␤ 1/250, anti-PKC ␦ 1/500, anti-PKC⑀ 1/1000, anti-PKC␥ 1/5000, anti-PKC 1/250 and rabbit anti-PKC 1/1000 in 5% non-fat milk powder) for 1 h at room temperature. After rinsing with 0.1% Tween-20 in Tris-buffered saline, the membranes were incubated with either goat antimouse IgG:HRP conjugate (1/2000 in 5% non-fat milk powder) or goat anti-rabbit IgG:HRP conjugate (1/2000 in 5% non-fat milk powder) for 1 h at room temperature.
Visualization of the antigenic reaction was carried out using the enhanced chemiluminesence (ECL) technique. The membrane was then exposed to ECL film for empirically determined periods and the optical density × area of the chemiluminescent reaction was determined using computer assisted densitometry (MCID M1 analysis system, Imaging Research Inc, Catherine, Ont, Canada).
Protein kinase C assay
The PKC assay was carried out using the Signa TECT  protein kinase C assay kit from Promega. The basal reactions were carried out in 20 mM Tris-HCl (pH 7.5), 10 mM MgCl 2 , 0.25 mM EGTA, 0.4 mM CaCl 2 , and 0.1 mg ml −1 bovine serum albumin with 0.1 mM ATP [␥-32 P]ATP at a final concentration of 0.1 Ci and the biotinylated substrate (neurogranin peptide) present at a final concentration of 100 M. Activated reactions were carried out as for basal reactions, but in the presence of 0.32 mg ml −1 phosphatidylserine and 0.032 mg ml −1 1,2-diacylglycerol. The reactions were incubated at 30°C for 5 min before being terminated with 7.5 M guanidine hydrochloride. The reaction mixtures were dotted onto the SAM 2  biotin capture membrane, which was thoroughly washed before being counted in NK for the chlorpromazine equivalent denotes subjects with schizophrenia who were known to have been receiving antipsychotic medication but had no recorded dose. The subject with no entry in the chlorpromazine equivalent column had not been receiving antipsychotic medication for 5 years prior to death.
a Packard Tricarb LSA2100. From these results basal PKC activity, activated PKC activity, PKC activity (activated minus basal) and percentage activation were calculated. In order to assess the specificity of the assay, the experiments were repeated in the presence of the selective PKC inhibitor, Gö 6976, at a final concentration of 5 nM.
Statistical analysis
Having ascertained that the results met the criteria for normal distribution using the Kolmogorov-Smirnov
Molecular Psychiatry test, comparisons between the diagnostic groups were made with the Student's t-test. Relationships between experimental parameters and various potential confounding factors were analyzed using Pearson single product moment correlations calculated using an assumed straight line fit. Finally, the relatively high incidence of suicide in schizophrenia makes it a possible confounding factor as protein kinase C has been reported to be altered in suicide. 12 Therefore, where significant differences are identified between schizophrenics and controls, further analysis using t-tests will be carried out to determine the effect of suicide in the population as a whole and within diagnostic cohorts. All statistical analyses were carried out using GraphPad Prism Version 3.0 for Windows (GraphPad Software Inc, San Diego, CA, USA).
Results
Demographics
There were no significant differences between the age, PMI or FT of the schizophrenic and control subjects. Brain pH was significantly lower (6.15 ± 0.1 vs 6.40 ± 0.03) for the schizophrenic group compared to the control group (Table 1) . ; P Ͻ 0.05, see Figure 1 ). There was also a small, but significant, reduction in the affinity of [ 3 H]PDBu binding in the tissue from schizophrenic subjects compared to that from control subjects (mean K D ± SEM: 4.64 ± 0.34 nM vs 2.95 ± 0.35 nM; P Ͻ 0.005, see Figure 1 ). All Scatchard plots were linear and the Hill coefficients were close to unity (mean ± SEM: 1.005 ± 0.011 for the schizophrenic group vs 1.027 ± 0.009 for the control group).
Western blots
There were no significant differences between the levels of the PKC ␣, ␤, ␥, ⑀ or isoforms in the PHG of schizophrenic and control subjects (Figure 2 ). Levels of both ␦ and isoforms in the PHG were below the detection limits of this Western blot technique. 
Protein kinase C assay
There were no significant differences between the basal, activated or percentage activation levels of PKC in PHG from schizophrenic and control subjects (Figure 3) . Gö 6976 at a final concentration of 5 nM reduced the PKC activity by 48.8% in extracts from subjects with schizophrenia and 49.5% in extracts from control subjects (data not shown).
Confounding factors
There were no significant correlations between any of the measures of [ 3 H]PDBu binding, levels of any PKC isoform or PKC activity. There were no significant correlations between any of the biochemical parameters measured in this study and the variables related to donor/tissue status (age, PMI, pH, FT or DOI and Figure 3 Levels of protein kinase C activity (mean ± SEM), expressed as activity, basal and activated, and percent activation in partially purified membrane preparations of the PHG, obtained at autopsy, from 12 schizophrenic and 12 control subjects.
chlorpromazine equivalents for subjects with schizophrenia). Further analysis showed that in neither the population as a whole nor the schizophrenic cohort was suicide a significant factor in relation to either the density or affinity of [ 3 H]PDBu binding. An analysis of the control as a separate cohort was not completed because only two of the subjects died as a result of suicide.
Discussion
Using particulate membranes, this study confirmed the results from our previous study, 1 with a decrease in the density of [ 3 H]PDBu binding in the PHG from subjects with schizophrenia. In addition, the current study also showed a small, but significant, decrease in the affinity of [ 3 H]PDBu binding to particulate membranes from the PHG from schizophrenic subjects. At this stage it is not possible to predict whether a change in affinity, of the magnitude we observed in the tissue from schizophrenic subjects who died by suicide, would have physiological consequences.
In the main, phorbol esters bind with high affinity to PKC, a key enzyme which mediates a second messenger system. 6 Therefore, the decrease in the density of [ 3 H]PDBu binding we measured in the PHG would be predicted to be due to a change in the levels of PKC isoforms, capable of binding phorbol esters, in the PHG. However, in this study, Western blot analysis suggests that there is no change, of a high enough magnitude to account for the change in [ 3 H]PDBu binding, in any of the PKC isoforms which bind phorbol esters in the PHG from subjects with schizophrenia. It should be taken into account that the levels of ␦ and isoforms were too low to be measured by Western blot analysis. However, such low levels of PKC isoforms would be unlikely to make a significant contribution to phorbol ester binding in the PHG. Furthermore, the antibody raised against PKC␤ does not distinguish between the splice variants ␤I and ␤II, so the values recorded for the ␤ isoform are the sum of the two variants. Therefore, if there are changes in either the ␤I or ␤II isoform in the PHG from subjects with schizophrenia, it must be masked by a compensatory change in the other isoform since the overall levels of the ␤ isoforms were unchanged.
The absence of change in any of the PKC isoforms is in agreement with our finding that the overall activity of PKC is not changed in the PHG from schizophrenic subjects. Together, the Western blot and the enzyme activity data suggest that PKC is not altered in the PHG from schizophrenic subjects.
With postmortem studies, there is always the question of whether the drugs ingested by the subjects during their lifetime have affected the outcome of the experiments. Although it has previously been reported that the antipsychotics haloperidol, chlorpromazine and clozapine can reduce the levels of PKC protein, mRNA and activity in rats, 14 16, 17 One of these sites, n-chimaerin, is a protein with a phorbol ester binding domain similar to that of PKC. 18 N-chimaerin is widely expressed in rat brain and has been shown to be present in the rat hippocampus. Nchimaerin is a rac21 GTPase activating protein, which moves from the cytosol to the membrane upon activation. 19 Rac21 is thought to be involved in cell growth and differentiation. 20 Although N-chimaerin in rodents was identified using probes based on human DNA sequences, its presence has yet to be demonstrated in the human central nervous system.
Another protein, which is present in the mammalian brain and binds [ 3 H]PDBu, is Munc13. 17 Munc13 is the mammalian homologue of unc-13p found in Caenorhabditis elegans; there are three isoforms, Munc13-1 to Munc13-3. Interestingly, in the context of changes in brain tissue obtained from schizophrenic subjects, all Munc13 isoforms are found presynaptically and are thought to be involved in the regulation of neurotransmitter release 17 and so could play an important role in the pathology of schizophrenia. More specifically, Munc13-1 has been shown to be necessary for the maturation of glutamatergic vesicles in presynaptic neurons, 21 a neurotransmitter system thought to be altered in schizophrenia. 22 To date, all the work relating to Munc13 isoforms has been carried out in rodents, although a human homologue has been reported. 23 In conclusion, our data suggest that the decrease in [ 3 H]PDBu binding in the PHG from subjects with schizophrenia is not due to changes in the levels of those PKC isoforms known to be capable of binding phorbol esters. This raises the possibility that changes in the levels of other molecules capable of binding phorbol esters are occurring in the PHG of schizophrenic subjects. The exact cause of these changes in [ 3 H]PDBu binding and its possible implications in the pathogenesis of schizophrenia remain to be elucidated but point to other candidate molecules which may have a role in the pathology of schizophrenia.
